RecruitingPhase 3NCT06321601
Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.
Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amgen
- Principal Investigator
- MDAmgen
- Intervention
- Avacopan(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 6-17 years · All sexes
- Timeline
- 2024 – 2028
Study locations (30)
- Emory University, Atlanta, Georgia, United States
- Riley Hospital for Children, Indianapolis, Indiana, United States
- University of Minnesota Masonic Childrens Hospital Discovery Clinic, Minneapolis, Minnesota, United States
- Cohen Children Medical Center, Lake Success, New York, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- Wake Forest University Health Sciences, Charlotte, North Carolina, United States
- Akron Childrens Hospital, Akron, Ohio, United States
- Cleveland Clinic Foundation, Cleveland, Ohio, United States
- University of Pittsburgh Medical Center Childrens Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Texas Childrens Hospital, Houston, Texas, United States
- Universitair Ziekenhuis Gent, Ghent, Belgium
- Universitair Ziekenhuis Leuven - Gasthuisberg, Leuven, Belgium
- Alberta Childrens Hospital, Calgary, Alberta, Canada
- Stollery Childrens Hospital, Edmonton, Alberta, Canada
- CHU Sainte Justine, Montreal, Quebec, Canada
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06321601 on ClinicalTrials.govOther trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07556484Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeMayo Clinic
- RECRUITINGEARLY PHASE1NCT07507201Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNCT07258524PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisUniversity of Edinburgh
- RECRUITINGPHASE1NCT07315087CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT06983821Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)Ottawa Hospital Research Institute
- RECRUITINGPHASE3NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisStaidson (Beijing) Biopharmaceuticals Co., Ltd
- RECRUITINGNCT07151521(68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRuijin Hospital
See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →